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Abstract: Metal-catalysed oxidation (MCO) may play a causative role in the pathogenesis of Alzheimer’s disease (AD). Amyloid β
peptide (Aβ), the major biomarker of AD, in the presence of copper ions reduces Cu2+ to Cu+ and catalyses the formation of H2O2
that subsequently induces radicals through Fenton chemistry. Aβ is also subject to attack by free radicals, where the presence of
Cu2+ in conjunction with H2O2 catalyses oxygenation, primarily at the methionine sulfur atom. This work investigates MCO of Aβ,
to gain further insight into the role of oxidative stress in AD. By combining a fluorescence assay with gel electrophoresis to monitor
MCO reactions of Aβ (1–28) in the presence and absence of methionine it was determined that methionine can both protect some
residues against MCO and promote the oxidation of Tyr(10) specifically. Electrospray ionization mass spectrometric analysis of
methionine MCO products indicated the formation of methionine sulfoxide, methionine sulfone and related hydroxylated products.
Similar products could be formed from the oxidation of Met(35) of Aβ and may relate to changes in properties of the peptide
following MCO. Copyright © 2004 European Peptide Society and John Wiley & Sons, Ltd.
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INTRODUCTION
Metal-catalysed oxidation (MCO) gives rise to highly
reactive intermediates such as hydroxyl radicals which
lead to damage of bio-molecules and are implicated
in aging and the pathogenesis of neurodegenerative
diseases, including Alzheimer’s disease (AD) [1,2]. AD
is characterized by the accumulation of senile plaques
mainly composed of aggregated amyloid β-peptide (Aβ).
Aβ is primarily a 40–42 amino acid peptide that
is a proteolytic product derived from the β amyloid
precursor protein (APP) (for review see [3–5]).
There are many indications that oxidative damage
plays a causative role in AD [6], including: metal
ions, especially iron, copper and zinc, being elevated
in the brains of AD patients [7–10] and implicated in
the catalytic activity that may produce free radicals;
antioxidants and metal chelators have shown promise
as potential treatments for AD [11–15]; and the toxicity
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of Aβ is eliminated by free radical scavengers in vitro
[16,17].
Different studies have indicated that the formation
of free radicals by Aβ occurs through interactions
with Cu2+ where the peptide reduces Cu2+ to Cu+
[18–23]. This catalytic process leads to the formation
of H2O2 with the subsequent production of radicals
such as the hydroxyl radical through Fenton chemistry
[18,20,24]. Additionally, Aβ itself is subject to attack
by free radicals, where the presence of Cu2+ can
catalyse oxygenation, mainly at the methionine sulfur
atom Met(35) [25,17], and dityrosine formation [26,23].
The most common source of reactive oxygen species
(ROS) is H2O2, which in the presence of redox active
metal ions Fe2+ or Cu+ generates the hydroxyl radical
(Fenton reaction).
Met(35) has been reported to play an important role
in the redox mediated toxicity of Aβ [1,27,17]. As
reviewed by Varadarajan et al. [1], the accumulated
data support a vital role for the methionine residue of
Aβ peptide in oxidative stress and neurotoxicological
properties of this peptide. Evidence includes: elevation
of methionine oxidation in senile plaques which recently
has been shown by Raman spectroscopy [28]; formation
of ROS by the shorter fragments of β-amyloid peptide
that contain the methionine residue, such as Aβ(25–35)
and Aβ(32–35) [29]; substitution of the methionine by
norleucine prevents toxicity [30]; and replacement of
a single sulfur atom in the methionine residue of the
peptide with a methylene (CH2) has been reported to
inhibit the toxicity of Aβ and the associated oxidative
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stress to cultured hippocampal neurons [31]. Therefore,
it has been hypothesized that the oxidative state of
the Met(35) residue sulfur in Aβ has implications for
initiation of free radicals and oxidative stress [32,2],
and the neurotoxicity of Aβ in AD [32,31,33],
In general, MCO of methionine (methionyl) residues
results in oxidation of the sulfur to methionine sulfoxide
Met(O) [34,35]. This oxidation product is known to
occur in the presence of H2O2 even without the metal
ion [36,37]. MCO is suggested to result from direct
oxidation [38], with a higher rate at pH 8.5 [39], and
Cu2+ catalysed this oxidation only at low reactant
concentration [39]. The rate of oxidation appears to
be higher in proteins than for the free amino acid [40].
Oxidation of the sulfur increases the hydrophilicity of
the protein and can induce conformational changes [41]
in a variety of proteins including Aβ as shown by us
and other groups [42,43,17]. Met(35) oxidation causes
partial conversion of Aβ from β-sheet to random coil
and decreases Aβ aggregation [42–44]. Additionally,
Met(35) oxidized Aβ is both soluble and toxic to
neuronal cells [17] and may prove to play an important
role in AD. Methionine also has been reported to protect
other residues from MCO [45]. Hence, investigation of
MCO of methionine is important, as is the identification
of stable and suitable MCO methionine products that
may be used as a biomarker for MCO of proteins and
peptides in biological systems.
The goal was to study changes to Aβ peptides under
conditions of MCO, and to investigate the role that
methionine plays in regulating MCO, to gain further
insights into the role of oxidative stress in AD. To
this end, techniques were developed to study MCO of
amino acids and the study was extended to Aβ(1–28),
a shorter version of the amyloid β-peptide. It was
demonstrated that: (i) MCO of amino acids and peptides
can be monitored using a fluorescence plate reader,
with His and Tyr able to be selectively monitored
depending upon the wavelength chosen; (ii) His, Phe
and Tyr are most sensitive to MCO and also most readily
monitored using this technique; and (iii) Met appears
to protect His of Aβ(1–28) but promotes Tyr oxidation
during MCO. This report shows that in the presence
of exogenous methionine, MCO of Aβ(1–28) generated
fluorescent products specific for tyrosine modification
and caused formation of higher oligomers of Aβ(1–28),
while in the absence of methionine, MCO of Aβ(1–28)
generated fluorescent products mainly due to histidine
and phenylalanine modifications, illustrating the role of
methionine in regulating the oxidation products of Aβ.
EXPERIMENTAL PROCEDURES
Materials
All chemicals were purchased from BDH Chemicals (Poole,
England), Sigma Chemical Co. (St Louis, USA) and Musashi
(Melbourne, Australia) with the highest available quality and
purity. All solvents were HPLC grade.
Aβ peptides were synthesized using manual solid-phase
(Boc) amino acid chemistry as described previously [46].
Electrophoretic molecular weight markers and reagents
for enhanced chemiluminescence (ECL) were purchased from
Amersham Pharmacia Biotech (Buckinghamshire, UK). Pre-
cast Tris-tricine gels (Novex) were obtained from Invitrogen
Life Technologies (Carlsbad, CA, USA) and Trans-Blot nitrocel-
lullose membrane were purchased from BioRad Laboratories
(Hercules, CA, USA).
Instrumentation
High performance liquid chromatography (HPLC) was per-
formed using a Waters system with dual 510 pumps and
a model 996-photodiode array detector controlled using Mil-
lennium software (Milford, USA). Data were recorded on a
Millennium 32 data collection package.
A fluorescence microplate reader (fMax) with incubator
and SOFTmaxPRO software (Sunnyvale, USA) were used.
Fluorescence plate reader measurements were carried out at
25 °C using the following filters: (λex 355 nm/λem 460 nm,
λex 485 nm/λem 538 nm, λex 544 nm/λem 590 nm and
λex 584 nm/λem 612 nm).
Electrospray ionization mass spectrometry (ESI-MS) was
performed using a Micromass Quattro II triple quadrupole
instrument (Manchester, UK) using positive ionmode. Samples
were introduced to the source via a Hewlett Packard (HP1100)
LC system (Palo Alto, USA) equipped with solvent degasser,
binary pumps and auto-sampler. Different buffer solutions
(either 0.1% formic acid or ammonium formate in MilliQ
water : acetonitrile (50 : 50)) were fed at 40 μl/min to the MS
probe. ESI-MS samples were dissolved in appropriate volumes
of 1% formic acid. Chelex 100 was used for removal of Cu2+
to avoid suppression of the MS signal by the metal ion. Data
were acquired in MCA mode from 90 to 1000 Da in 10 s scans,
with an ion source at 80 °C and sampling cone voltages of 25
or 30, 40 or 60 V. The voltages were selected and the high
voltage value (60 V) used for fragmentation of tested samples
and further identification.
Methods
Amino acid-/metal catalysed oxidation. 5 mg of each amino
acid was dissolved in 10 ml of PBS (pH 7.4); 4 ml of each
solution was mixed with 46 μl of 20 mM CuCl2 by stirring at
37 °C; the samples were sonicated for 2 min and kept in closed
vials, bubbled with nitrogen gas for 3 min to ensure removal
of oxygen then 40, 30, 20 and 10 μl of 3% H2O2 was added
over 3 days. Excess amounts of Chelex 100 were added to the
flasks at reaction end to ensure removal of any trace copper
ions. The reaction was quenched by freezing under liquid
nitrogen and freeze-dried. The dried samples and the controls
were redissolved in 4 ml of MilliQ water and analysed using a
fluorescence microplate reader and Fmoc amino acid analysis.
An alternative method was used to suit the conditions
required for ESI-MS analysis. The size of the samples was
multiplied by 10; PBS was replaced by ammonium acetate
buffer with the same pH and H2O2/amino acid 10 : 1 molar
ratio was added immediately. In addition, the incubation
time was reduced to 1 day. Excess amounts of Chelex 100
Copyright © 2004 European Peptide Society and John Wiley & Sons, Ltd. J. Peptide Sci. 11: 353–360 (2005)
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Table 1 Scheme Used to Determine Metal Catalysed Oxidation of Aβ(1–28) Peptide































a All the samples were made up to 1 ml by addition of 10 mM ammonium acetate buffer (pH 7.4) and
the control samples included the same compositions as 1–8 but CH3CN :H2O replaced the peptide
solution.
b 10 μl of 3.0 mM H2O2.
c 100 μl of 3.0 mM CuCl.
d 100 μl of 3.0 mM of CuCl2.
e 10 μl of 300 μM methionine.
f 10 μl of horseradish peroxidase solution (0.1 mg in 1 ml of ammonium acetate buffer).
g 100 μl of 30 μM Aβ (1–28) (0.1 mg dissolved in H2O : CH3CN, 1 : 1 v/v).
were added to the flasks at reaction end to ensure removal
of any trace copper ions. The reactions were decanted into
clean tubes and frozen in liquid nitrogen and lyophilized. The
dried samples were analysed using ESI-MS and fractions were
collected from HPLC for Fmoc-amino acid analysis.
Aβ peptide metal catalysed oxidation. Aβ(1–28) (0.01
mg/ml or 3 μM) in ammonium acetate buffer (0.01 M,
pH 7.4) was incubated with H2O2 (1 μg/ml or 30 μM)
in CuCl (3 μg/ml or 31 μM) or CuCl2 (4 μg/ml or
31 μM), with and without methionine (0.46 μg/ml or
3.1 μM) (see Table 1). These solutions were vortexed for
10 s and incubated for 1 day at 37 °C. Chelex 100 was
added to remove Cu ions and the samples freeze-dried.
The samples and the controls were redissolved in MilliQ
water or MilliQ water : acetonitrile (1 : 1) and analysed by
ESI-MS, UV/Vis, fluorescence microplate reader and gel
electrophoresis-polyacrylamide gel electrophoresis utilizing
the WO2 antibody as described below.
All MCO reactions were done in the absence of light to avoid
photochemical reactions [47].
Fmoc-amino acid analysis. Fmoc (fluorenylmethoxycarbonyl)
amino acid analysis was carried out using a slight modification
of Haynes’s method [48,49]. 100 μl of amino acid with
MCO reaction mixture or the control sample (with the same
concentration of the amino acid but without MCO components)
in 1.5 ml Eppendorf tube was mixed with 5 μl of borate
buffer (pH 8.5, 16 mM), followed by addition of 100 μl of
Fmoc reagent solution (6 mg in 1.5 MilliQ water), agitated
for 90 s and followed by the addition of 60 μl cleavage
reagent (680 μl of 0.1 M EDTA and 20 M NaOH + 300 μl
of hydroxylamine hydrochloride in 1 ml MilliQ water + 80 μl
of 2-(methylthio)ethanol) prepared fresh daily. The reaction
components were mixed and allowed to stand for 3.5 min. The
reaction was stopped by addition of 140 μl of the quenching
reagent (2 ml glacial acetic dissolved in 8 ml acetonitrile
acid). 20 μl of the reaction mixture was injected into the
HPLC system.
Polyacrylamide gel electrophoresis (PAGE) and Western
blotting. MCO of Aβ(1–28) was monitored by SDS–PAGE. The
dried samples were dissolved in sample buffer (8 M urea, 8%
sodium dodecyl sulfate (SDS), 30% glycerol, 100 mM tricine,
0.01% phenol red and 10% mercaptoethanol), and subjected
to PAGE and calibrated Western blot according to previously
described procedures [50]. Western blots were probed for Aβ
species using the monoclonal antibody WO2 which recognizes
residues 5–8 [51].
RESULTS
Metal Catalysed Oxidation of Amino Acids
As a prelude to attempting to understand MCO
modifications to Aβ, initially MCO mediated changes to
the individual amino acids were investigated. The object
of this study was to develop an assay for monitoring the
changes in peptide residues due to Cu2+ and H2O2
oxidation. Fmoc amino acids analysis was used to
monitor the impact of MCO on the different amino acids.
Selected amino acids were assayed using a fluorescence
plate reader after MCO. Two of the readily available
plate filters were found to be specific for monitoring the
modification of tyrosine, phenylalanine and histidine.
Fmoc-amino acid analysis. Fmoc-amino acid analysis
was used to overcome difficulties in analysis by RP-
HPLC of amino acids and their products fromMCO [48].
The amino acid was derivatized with the Fmoc group
Copyright © 2004 European Peptide Society and John Wiley & Sons, Ltd. J. Peptide Sci. 11: 353–360 (2005)
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Figure 1 Percentage of amino acid oxidized by MCO after
incubation for 3 days with Cu2+/H202 in PBS (pH 7.4) at 37 °C.
Results obtained from HPLC analysis of Fmoc amino acid.
to reduce polarity and prevent the amino acid from
eluting with the solvent peak. Furthermore, the Fmoc
group enhances the sensitivity of amino acids to UV-Vis
and fluorescence detectors. This method was applied
to quantify amino acid oxidation in the Cu2+/H2O2
system. Oxidation was quantified by calculating the
difference in peak area for the starting Fmoc-amino acid
before and after reaction (Figure 1). The results show
that aliphatic amino acids have the greatest stability
against MCO, especially alanine, isoleucine, leucine and
glycine. The remaining amino acids, except tryptophan,
are modified under conditions of MCO.
Fluorescence microplate reader analysis of MCO of
amino acids. A fluorescence microplate reader was
used to determine any changes in fluorescence of amino
acids following oxidation conditions as a possible assay
for oxidation of Aβ residues. The four available filters
with the microplate reader (λex 355 nm/λem 460 nm,
λex 485 nm/λem 538 nm, λex 544 nm/λem 590 nm and
λex 584 nm/λex 661 nm) were tested; but only the first
two filters showed positive results (Figure 2).
Filter (λex 355 nm/λem 460 nm) showed an increase
in fluorescence from MCO of histidine, phenylalanine
and tyrosine. Both histidine and phenylalanine MCO
products produced the largest increase in fluorescence
(see Figure 2(a)). Consequently, this filter can be used to
monitor MCO of histidine and phenylalanine in peptides
and proteins. The filter (λex 485 nm/λem 538 nm) was
the most sensitive to the fluorescent products of
tyrosine oxidation (Figure 2(b)). Aromatic residues are
known to fluoresce, so it is not surprising that His, Phe
and Tyr showed the strongest fluorescence after MCO.
It should be noted that the presence of Cu2+ quenched
the fluorescence signal of some amino acids, especially
tyrosine products (such as dityrosine) since Cu2+ was






















Figure 2 Change in fluorescence intensity after reaction
of amino acids with Cu2+/H2O2 as monitored by fluo-
rescence microplate reader (,amino acid + Cu2+ prior to
reaction; ,amino acid + Cu2+/H2O2 after reaction). (a) Plate
reader filter (λex 355 nm/λem 460 nm); (b) Plate reader filter
(λex 485 nm/λem 538 nm).
that the MCO products of some amino acids formed
strong ligands for Cu2+.
ESI-MS identification of MCO of methionine. ESI-
MS analysis of the Cu2+-MCO reaction mixtures of
methionine showed fragmented forms of the amino
acids (data not shown) even at low cone voltage (20 V).
Methionine showed a peak with loss of a CO2H group
(45.1 mu). Other masses for fragmented methionine
were detected and could be due to the catalytic activity
of copper ions causing fragmentation of amino acids in
the ESI [52–54]. Fmoc-amino acid analysis was used to
isolate the modified forms of methionine by MCO. ESI-
MS data indicated the formation of the usual oxidation
products as found for H2O2 without Cu
2+, i.e. formation
of Met(O), but also showed formation of methionine
sulfone (dioxide) Met(O)2. In addition, the hydroxylated
form also appeared in the MS, as indicated by the
additional proton (i.e., O + 1 mu) and/or sodium mass
(i.e., O + 23 mu).
Metal catalysed oxidation of Aβ(1–28). Aβ(1–28) was
used as a model for Aβ(1–40) and Aβ(1–42) because
it is more soluble, aggregates less, contains all the
non-aliphatic amino acids (except Met (35)) and all
the residues required for metal binding [55,22]. The
addition of exogenous methionine has previously been
shown to induce redox reactions [22] with Aβ(1–28)
and Cu2+ and was, therefore, added (1 : 1 molar ratio)
to some samples to test its role in MCO of the peptide.
Also Cu+ and Cu2+ were used to identify the importance
of the metal ion oxidation state to the conversion and
formation of reactive oxygen species (ROS) in MCO and
Fenton reaction (conversion of Cu+ to Cu2+).
Fluorescence microplate reader analysis of MCO
of Aβ(1–28). The fluorescence microplate results



































Figure 3 Fluorescence intensity of Aβ(1–28) and H2O2 after
incubation with Cu+ or Cu2+ and methionine. The sam-
ples are: 1 (H2O2 + Aβ(1–28)), 2 (H2O2 + Aβ(1–28) + Cu+),
3 (H2O2 + Aβ(1–28) + Cu+ + methionine), 4 (H2O2 + Aβ(1–28)
+ Cu2+) and 5 (H2O2 + Aβ(1–28) + Cu2+ + methionine).
(a) Plate reader filter (λex 355 nm/λem 460 nm); (b) Plate
reader filter (λex485 nm, λem 538 nm).
for the peptide under different MCO reaction con-
ditions are shown in Figure 3. Using the filter
(λex 355 nm/λem 460 nm) indicated a slight modifica-
tion of Aβ(1–28) in the presence of H2O2 and Cu
+ or
Cu2+ in comparison to that with H2O2 alone. Formation
of more fluorescent products was primarily due to both
histidine and phenylalanine modifications, as can be
seen with the individual amino acids in Figure 2(a). Sur-
prisingly, this modification was inhibited by the addi-
tion of methionine. However, the presence of methio-
nine appeared to promote the modification of tyrosine
(Tyr(10)) as indicated by the increase in the fluorescence
intensity using the λex485 nm/λem538 nm filter (see
Figure 2(b) and Figure 3(b)). The methionine itself does
not cause an increase in fluorescence as oxidized Met
products do not fluoresce (Figure 2) but the addition
of methionine results in an increase in oxidized tyro-
sine products. These results illustrate the importance
of methionine in MCO, in facilitating the modification
of Tyr(10) in Aβ(1–28). Unlike full-length Aβ, Aβ(1–28)
does not contain a Met residue, yet MCO of Tyr(10) is
enhanced by the addition of free methionine.
Gel electrophoresis-polyacrylamide gel electro-
phoresis. Gel electrophoresis was used to determine the
aggregated state of Aβ(1–28) after MCO modification.
Figure 4 Western blot of Aβ(1–28) samples under different
MCO conditions. The gel shows oligomerization and modi-
fication of the peptide, especially in presence of Cu2+ and
methionine.
The results are summarized in Figure 4 and show
that Aβ(1–28) in the presence of H2O2 and Cu ions
aggregated more readily to form higher oligomers. The
peptide with H2O2 and Cu
+ showed some aggregation
but with H2O2 and Cu2+ showed little intensity on
the gel, suggesting that modifications to the epitope
of the WO2 antibody had occurred. The published
epitope for this antibody is residues 5–8 (RHDS)
[51]. In the presence of methionine, H2O2 and Cu
+
a similar loss of intensity was observed suggesting
modifications to the antibody epitope, i.e. MCO of
histidine. The addition of methionine to the H2O2
and Cu2+ reaction with Aβ(1–28) changed the profile
of the reaction such that massive aggregation was
observed and there was no evidence of any interference
with the antibody epitope as immunoreactivity to
the WO2 antibodies was still observed, i.e. MCO of
tyrosine, which would not affect the RHDS residues.
These differences in the effects of Cu+ and Cu2+,
reflect the formation of different oxidation products of
Aβ(1–28) with modification of histidines and formation
of dityrosines [22], respectively.
DISCUSSION
Monitoring the modification of Aβ by MCO is difficult
partly because a variety of residues can undergo oxi-
dation and each can form multiple oxidation products
(see Figure 1). In addition, binding of metal ions such
as Cu2+ to a specific region may cause changes in the
conformation of the peptide that promote aggregation
[56] making analysis more difficult. Nevertheless, spe-
cific changes were observed, allowing conclusions to
be made about the role of specific residues such as
methionine and tyrosine in MCO of Aβ.
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Under oxidative conditions the Cu2+ bound to the
histidine residues of Aβ [22] induces modifications to
a variety of different residues. NMR results showed
that the imidazole ring is modified in the case of
histidine, and the results of amino acid analysis and
HPLC showed that phenylalanine formed Tyr, o-Tyr and
m-Try following MCO (data not shown). However, the
presence of methionine alters the profile of products
from the MCO, possibly by reducing Cu2+ to Cu+ as
shown by Curtain et al. [22], such that modification
of tyrosine residues is promoted (see Figures 2–4).
It was recently shown that when Cu2+ bound to
Aβ(1–42) is reduced to Cu+ by a reductant this process
is facilitated via a proton-coupled electron transfer
(PCET) involving Tyr(10). As the electron passes from
the reductant to the copper there is a concerted
transfer of a proton to Tyr(10), resulting in the phenol
oxygen being protonated and Tyr(10) being susceptible
to oxidative modification [57,23]. Reactions involving
PCET have become increasingly implicated in a range
of biological systems including charge transport in DNA
and enzymatic oxygen production [58].
Modifications to tyrosine residues include the forma-
tion of 3,4-dihydroxyphenylalanine (DOPA), dopamine,
dopamine quinone, dityrosine (DT), isoDT and dihy-
droxyindol [57]. DT (Cortho − Cortho linkage) and isoDT
(Cortho − O linkage) are the most stable structures of
these products [59,60]. Recent results from Atwood
et al. [26] have shown that Aβ(1–42) in the presence
of Cu/H2O2 forms dityrosine. These different tyrosine
linkages lead to the formation of higher oligomers and
facilitate peptide aggregation as shown in Figure 4. In
addition, Schoeneich and Williams [61] studying the
reaction of Aβ 1–16 with Cu/H2O2 by HPLC-MS/MS
detected 2-oxo-histidine, which is generated from the
oxidation of histidine residues of Aβ 1–16. Our cur-
rent study sits between these two reports and is able
to explain the apparent disparity in the results since
Aβ(1–28) does not contain Met(35). Without methio-
nine, histidines are modified and when methionine
is added to Aβ(1–28), modified forms of tyrosine are
produced, including dityrosine linkages. Our results
support recent work which showed a modification in
both histidine and tyrosine residue contents of Aβ pep-
tides by MCO of Cu2+ + H2O2 [62]. In addition, the
data support the suggestion that histidine and tyro-
sine residues are most vulnerable to metal mediated
oxidative attack [62].
Oxidation of the sulfur atom of the methionine
residue during MCO of Aβ peptides plays an important
role in peptide modification as recently reported [25,2],
where Met(35) is proposed to be the main source of ROS
from Aβ [2]. It was previously shown [17] that oxidation
of Met(35) leads to changes in Aβ structure and lipid
interactions but that the peptide is still neurotoxic.
Additionally Dong et al. have shown evidence that
extensive side chain oxidation occurs in Met(35) of Aβ
in the senile plaque of diseased brain [28].
The Western blot results revealed that the aggrega-
tion of Aβ(1–28) in the presence of copper ions induces
modifications which prevent the antibody binding these
forms (Figure 4) as seen for Aβ(1–28) + H2O2 + Cu2+,
which suggests that in this case residues 5–8 (RHDS)
are modified. The presence of methionine inhibited
these modifications, and instead promoted modification
of Tyr10 (as shown by fluorescence plate reader results).
The results support the hypothesis of methionine act-
ing as a scavenger, which prevents the modification of
amino acids such as histidine in Aβ but allows modifi-
cation to tyrosine which is not part of the epitope of the
WO2 antibody.
Methionine adducts modified by MCO were identified
by ESI-MS. The modified forms of methionine were
isolated as Fmoc amino acid derivatives (Figure 1(b))
and were not detected by direct RP-HPLC analysis
as they are most likely to be of higher polarity
than methionine. These products are summarized in
Figure 5. Higher oxidized compounds of methionine
may have an additional oxygen at the sulfur atom or to
one of the carbon atoms, or addition of a perhydroxyl
group (OOH) at the sulfur atom [63,64]. Sulfides
oxidized to sulfoxides and then sulfones are known
reactions for sulfur atoms in different compounds [65],
but it has been shown by MS that copper ions catalysed
the formation of these products in addition to the other
active oxidation products. Some of these products have
been identified recently in other oxidation reactions, e.g.
oxohydroxylsulfur produced from the photochemical
reaction of H2O2 with DMSO [66]. Furthermore, the
hydroxyl radical formed from a Fenton-like reaction





























Figure 5 Different forms of sulfur in methionine residue
as a result of metal catalysed oxidation (MCO). These
include formation of: (a) known sulfoxides or oxo-sulfur Me(O),
(b) sulfones or dioxosulfur (methionine sulfone) Met(O2), and
(c) other hydroxyl sulfur compounds, such as (i) hydroxyl
sulfur, (ii) oxohydroxylsulfur, (iii) dihydroxyl and (d) their
sodium salts. Low yields of higher oxidized forms could induce
(e) methylide sulfoxonium ion, and (f) sulfonic acid derivative
with additional oxygen atoms Met(O3).
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form oxohydroxylsulfur derivatives which decay with
a 100 ns half-life to form sulfone derivatives [67], but
our MS suggests that the oxohydroxylsulfur derivative
of methionine is more stable. Similar products may be
formed from the oxidation of Met(35) of Aβ and have
implications to conformational changes in the peptide
[68,69]. Further, oxidized products of MCO of Aβ may
be detected by fluorescence assays and used to study
structure-function relationships.
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